{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T17:20:05Z","timestamp":1787678405998,"version":"build-2784847793"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["CA188252"],"award-info":[{"award-number":["CA188252"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Michigan Forbes Institute for Cancer Discovery"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.ejmech.2018.09.037","type":"journal-article","created":{"date-parts":[[2018,9,15]],"date-time":"2018-09-15T23:12:45Z","timestamp":1537053165000},"page":"884-895","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Synthesis and mechanistic studies of quinolin-chlorobenzothioate derivatives with proteasome inhibitory activity in pancreatic cancer cell lines"],"prefix":"10.1016","volume":"158","author":[{"given":"Shuai","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanghan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Ljungman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nouri","family":"Neamati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2018.09.037_bib1","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","article-title":"Proteasome inhibitors in cancer therapy","volume":"14","author":"Manasanch","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2018.09.037_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.freeradbiomed.2016.12.007","article-title":"Proteasome inhibitors in cancer therapy: treatment regimen and peripheral neuropathy as a side effect","volume":"103","author":"Kaplan","year":"2017","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.ejmech.2018.09.037_bib3","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1083\/jcb.201210077","article-title":"Development of proteasome inhibitors as research tools and cancer drugs","volume":"199","author":"Goldberg","year":"2012","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.ejmech.2018.09.037_bib4","doi-asserted-by":"crossref","first-page":"T1","DOI":"10.1530\/ERC-14-0005","article-title":"The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors","volume":"22","author":"Johnson","year":"2015","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.ejmech.2018.09.037_bib5","series-title":"Resistance to Proteasome Inhibitors in Cancer: Molecular Mechanisms and Strategies to Overcome Resistance","first-page":"47","article-title":"Resistance to proteasome inhibitors in multiple myeloma","author":"Cottini","year":"2014"},{"key":"10.1016\/j.ejmech.2018.09.037_bib6","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(04)15841-8","article-title":"Pancreatic cancer","volume":"363","author":"Li","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2018.09.037_bib7","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/nrgastro.2017.182","article-title":"Pancreatic cancer in 2017: rebooting pancreatic cancer knowledge and treatment options","volume":"15","author":"Semaan","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejmech.2018.09.037_bib8","doi-asserted-by":"crossref","first-page":"16022","DOI":"10.1038\/nrdp.2016.22","article-title":"Pancreatic cancer","volume":"2","author":"Kleeff","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.ejmech.2018.09.037_bib9","doi-asserted-by":"crossref","first-page":"682","DOI":"10.4251\/wjgo.v8.i9.682","article-title":"Pancreatic cancer: new hopes after first line treatment, World","volume":"8","author":"Aroldi","year":"2016","journal-title":"J.\u00a0Gastrointest. Oncol."},{"key":"10.1016\/j.ejmech.2018.09.037_bib10","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1177\/1756283X17713879","article-title":"Current status on the place of folfirinox in metastatic pancreatic cancer and future directions","volume":"10","author":"Lambert","year":"2017","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.ejmech.2018.09.037_bib11","doi-asserted-by":"crossref","first-page":"4924","DOI":"10.1002\/cncr.30944","article-title":"Inhibiting heat shock protein 90 and the ubiquitin-proteasome pathway impairs metabolic homeostasis and leads to cell death in human pancreatic cancer cells","volume":"123","author":"Belalcazar","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ejmech.2018.09.037_bib12","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1080\/15548627.2016.1191722","article-title":"Simultaneous inhibition of the ubiquitin-proteasome system and autophagy enhances apoptosis induced by er stress aggravators in human pancreatic cancer cells","volume":"12","author":"Li","year":"2016","journal-title":"Autophagy"},{"key":"10.1016\/j.ejmech.2018.09.037_bib13","doi-asserted-by":"crossref","first-page":"11658","DOI":"10.1158\/0008-5472.CAN-05-2370","article-title":"Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis","volume":"65","author":"Nawrocki","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2018.09.037_bib14","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.canlet.2016.08.018","article-title":"Proteasome activator subunit 3 promotes pancreatic cancer growth via c-myc-glycolysis signaling axis","volume":"386","author":"Guo","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2018.09.037_bib15","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nchembio.2326","article-title":"Capzimin is a potent and specific inhibitor of proteasome isopeptidase rpn11","volume":"13","author":"Li","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2018.09.037_bib16","doi-asserted-by":"crossref","first-page":"5231","DOI":"10.1021\/jm400282d","article-title":"Quinoline drug-heme interactions and implications for antimalarial cytostatic versus cytocidal activities","volume":"56","author":"Gorka","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.09.037_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.arabjc.2016.10.009","article-title":"Comprehensive review on current developments of quinoline-based anticancer agents","author":"Jain","year":"2016","journal-title":"Arab J Chem"},{"key":"10.1016\/j.ejmech.2018.09.037_bib18","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1021\/acsmedchemlett.5b00098","article-title":"Amino acid thioester derivatives: a highly promising scaffold for the development of metallo-beta-lactamase l1 inhibitors","volume":"6","author":"Liu","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2018.09.037_bib19","series-title":"Compositions and Methods for JAMM Protein Inhibition","author":"Zhou","year":"2014"},{"key":"10.1016\/j.ejmech.2018.09.037_bib20","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/cmdc.201700629","article-title":"Discovery and mechanistic elucidation of a class of protein disulfide isomerase inhibitors for the treatment of glioblastoma","volume":"13","author":"Kyani","year":"2018","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2018.09.037_bib21","doi-asserted-by":"crossref","first-page":"D412","DOI":"10.1093\/nar\/gkn760","article-title":"String 8--a global view on proteins and their functional interactions in 630 organisms","volume":"37","author":"Jensen","year":"2009","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2018.09.037_bib22","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2018.09.037_bib23","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/ng1180","article-title":"Pgc-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes","volume":"34","author":"Mootha","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejmech.2018.09.037_bib24","doi-asserted-by":"crossref","first-page":"10403","DOI":"10.1073\/pnas.96.18.10403","article-title":"Epoxomicin, a potent and selective proteasome inhibitor, exhibits in\u00a0vivo antiinflammatory activity","volume":"96","author":"Meng","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2018.09.037_bib25","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.cell.2017.10.049","article-title":"A\u00a0next generation connectivity map: L1000 platform and the first 1,000,000 profiles","volume":"171","author":"Subramanian","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2018.09.037_bib26","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1743-7563.2012.01535.x","article-title":"Mg132, a proteasome inhibitor, induces apoptosis in tumor cells","volume":"9","author":"Guo","year":"2013","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2018.09.037_bib27","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.1365-2141.2008.07066.x","article-title":"Redox homeostasis modulates the sensitivity of myeloma cells to bortezomib","volume":"141","author":"Nerini-Molteni","year":"2008","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejmech.2018.09.037_bib28","doi-asserted-by":"crossref","first-page":"66360","DOI":"10.18632\/oncotarget.11960","article-title":"Noncanonical sqstm1\/p62-nrf2 pathway activation mediates proteasome inhibitor resistance in multiple myeloma cells via redox, metabolic and translational reprogramming","volume":"7","author":"Riz","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2018.09.037_bib29","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.canlet.2016.03.005","article-title":"C\/ebpbeta regulates sensitivity to bortezomib in prostate cancer cells by inducing redd1 and autophagosome-lysosome fusion","volume":"375","author":"Barakat","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2018.09.037_bib30","first-page":"5317","article-title":"Gadd34 facilitates cell death resulting from proteasome inhibition","volume":"35","author":"Liu","year":"2015","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ejmech.2018.09.037_bib31","doi-asserted-by":"crossref","first-page":"306073","DOI":"10.1155\/2013\/306073","article-title":"Preventive and therapeutic effects of mg132 by activating nrf2-are signaling pathway on oxidative stress-induced cardiovascular and renal injury","volume":"2013","author":"Cui","year":"2013","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.ejmech.2018.09.037_bib32","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.bcp.2011.07.085","article-title":"Proteasome inhibitor mg132-induced apoptosis via er stress-mediated apoptotic pathway and its potentiation by protein tyrosine kinase p56lck in human jurkat t cells","volume":"82","author":"Park","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2018.09.037_bib33","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.2147\/OTT.S139686","article-title":"Identification of the anticancer effects of a novel proteasome inhibitor, ixazomib, on colorectal cancer using a combined method of microarray and bioinformatics analysis","volume":"10","author":"Fan","year":"2017","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.ejmech.2018.09.037_bib34","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41419-017-0195-0","article-title":"Preclinical evaluation of antitumor activity of the proteasome inhibitor mln2238 (ixazomib) in hepatocellular carcinoma cells","volume":"9","author":"Augello","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2018.09.037_bib35","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.mce.2013.11.009","article-title":"Hypoxia induces a hif-1 alpha dependent signaling cascade to make a complex metabolic switch in sgbs-adipocytes","volume":"383","author":"Leiherer","year":"2014","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.ejmech.2018.09.037_bib36","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/toxsci\/kfv012","article-title":"Regulation of toll-like receptor-mediated sestrin2 induction by ap-1, nrf2, and the ubiquitin-proteasome system in macrophages","volume":"144","author":"Kim","year":"2015","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.ejmech.2018.09.037_bib37","doi-asserted-by":"crossref","first-page":"e0183076","DOI":"10.1371\/journal.pone.0183076","article-title":"Antagonism of proteasome inhibitor-induced heme oxygenase-1 expression by pink1 mutation","volume":"12","author":"Sheng","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2018.09.037_bib38","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1038\/onc.2014.352","article-title":"Stress-induced inhibition of nonsense-mediated rna decay regulates intracellular cystine transport and intracellular glutathione through regulation of the cystine\/glutamate exchanger slc7a11","volume":"34","author":"Martin","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2018.09.037_bib39","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood-2007-11-120576","article-title":"Bortezomib inhibits tumor adaptation to hypoxia by stimulating the fih-mediated repression of hypoxia-inducible factor-1","volume":"111","author":"Shin","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2018.09.037_bib40","article-title":"Myeloid translocation gene-16 co-repressor promotes degradation of hypoxia-inducible factor 1","volume":"10","author":"Kumar","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2018.09.037_bib41","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1158\/2159-8290.CD-11-0234","article-title":"Functional metabolic screen identifies 6-phosphofructo-2-kinase\/fructose-2,6-biphosphatase 4 as an important regulator of prostate cancer cell survival","volume":"2","author":"Ros","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2018.09.037_bib42","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1038\/onc.2016.477","article-title":"6-phosphofructo-2-kinase\/fructose-2,6-biphosphatase 4 is essential for p53-null cancer cells","volume":"36","author":"Ros","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2018.09.037_bib43","doi-asserted-by":"crossref","first-page":"5662","DOI":"10.1038\/onc.2015.23","article-title":"Identification of 6-phosphofructo-2-kinase\/fructose-2,6-bisphosphatase as a novel autophagy regulator by high content shrna screening","volume":"34","author":"Strohecker","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2018.09.037_bib44","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1021\/acs.jmedchem.7b01463","article-title":"Design and synthesis of novel reactive oxygen species inducers for the treatment of pancreatic ductal adenocarcinoma","volume":"61","author":"Kuang","year":"2018","journal-title":"J.\u00a0Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418308092?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418308092?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,6]],"date-time":"2018-10-06T02:07:15Z","timestamp":1538791635000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523418308092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":44,"alternative-id":["S0223523418308092"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.09.037","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis and mechanistic studies of quinolin-chlorobenzothioate derivatives with proteasome inhibitory activity in pancreatic cancer cell lines","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.09.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}